Monro Muffler Brake Inc. (NASDAQ:MNRO) shares moved down -1.47% in last trading session and ended the day at $63.14. MNRO Gross Margin is 40.40% and its has a return on assets of 6.80%. Monro Muffler Brake Inc. (NASDAQ:MNRO) quarterly performance is -12.62%.
On 26 January, Monro Muffler Brake Inc. (NASDAQ:MNRO) reported fiscal third-quarter profit of $15.2 million. The Rochester, New York-based company said it had profit of 46 cents per share. Earnings, adjusted for non-recurring costs, were 51 cents per share. The automotive repair chain posted revenue of $238.9 million in the period, which did not meet Street forecasts. Four analysts surveyed by Zacks expected $239.3 million. For the current quarter ending in March, Monro said it expects revenue in the range of $232 million to $240 million.
Cape Bancorp, Inc. (NASDAQ:CBNJ) ended the last trading day at $12.54. Company weekly volatility is calculated as 2.46% and price to cash ratio as 3.57. Cape Bancorp, Inc. (NASDAQ:CBNJ) showed a weekly performance of -5.22%.
Cape Bancorp, Inc. (NASDAQ:CBNJ) announced that its Board of Directors declared a cash dividend of $0.10 per common share on January 18, 2016. The dividend is expected to be paid on or about February 16, 2016 to stockholders of record as of the close of business on February 1, 2016.
On 08 February, Inventergy Global, Inc. (NASDAQ:INVT) shares advanced 2.45% and was closed at $2.09. INVT EPS growth in last 5 year was -36.00%. Inventergy Global, Inc. (NASDAQ:INVT) year to date (YTD) performance is 29.81%.
Inventergy Global, Inc., (NASDAQ: INVT) (“Inventergy” or the “Company”), announced that it has been invited to present at the upcoming Source Capital 2016 Disruptive Growth & Healthcare Conference to be held on February 10-11, 2016 at the Convene Conference Center in New York City.
Prima Biomed Ltd. (NASDAQ:PBMD) shares moved down -6.25% in last trading session and ended the day at $0.90. Prima Biomed Ltd. (NASDAQ:PBMD) quarterly performance is -21.74%.
On 27 January, Prima BioMed Ltd (NASDAQ: PBMD) announced the granting of patent number US 9,244,059 entitled “Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease” by the United States Patent and Trademark Office.
Fluidigm Corporation (NASDAQ:FLDM) caters to the Healthcare space. It has a net profit margin of -43.70% and weekly performance is -15.19%. On the last day of trading company shares ended up at $5.47. Fluidigm Corporation (NASDAQ:FLDM) distance from 50-day simple moving average (SMA50) is -39.93%.
On 4 February, Fluidigm Corp. (NASDAQ:FLDM) reported a loss of $12.9 million in its fourth quarter. On a per-share basis, the South San Francisco, California-based company said it had a loss of 45 cents. Losses, adjusted for one-time gains and costs, were 24 cents per share. The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 48 cents per share. The company that makes equipment to control fluids posted revenue of $30.7 million in the period, also topping Street forecasts. Four analysts surveyed by Zacks expected $30.1 million.
Leave a Reply